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ABSTRACT
Objectives  Subjects with rheumatoid factor positive 
inﬂ  ammatory polyarthritis (IP) are known to have 
increased mortality from cardiovascular disease (CVD). A 
study was undertaken to examine the risk and baseline 
predictors of admission with CVD in patients with recent-
onset IP.
Methods  Subjects are recruited by the Norfolk Arthritis 
Register if they present to primary or secondary care 
with ≥2 swollen joints lasting ≥4 weeks. This analysis 
includes subjects recruited between 1995 and 1999. 
Baseline data on lifestyle, demographic characteristics, 
disease and treatment characteristics were collected. 
CVD admissions were identiﬁ  ed through record linkage 
with the only acute care hospital in the study region. 
First-episode hospitalisation rates were compared with 
those of the general population. Poisson regression was 
used to calculate the relative risk (RR) of admission for 
patients with IP (overall and for each risk factor). Death 
certiﬁ  cates were obtained from the national death 
register.
Results  800 patients with recent-onset IP were followed 
for a median of 7.0 years. 64 CVD-related hospitalisations 
were observed (11.7 per 1000 person-years). Patients 
with IP were twice as likely (RR=2.0; 95% CI 1.5 to 2.5) 
to be hospitalised for CVD as the general population. 
Difﬁ  culty walking at baseline was a signiﬁ  cant predictor 
of CVD admission and baseline non-steroidal anti-
inﬂ  ammatory drug use was associated with a reduced 
risk of CVD admission.
Conclusions  Patients with IP are at increased risk of 
CVD-related hospitalisation, within 7 years of symptom 
onset. Informing patients about lifestyle modiﬁ  cation may 
reduce the risk of CVD.
INTRODUCTION
It is now well established that patients with rheu-
matoid arthritis (RA) have increased mortality 
from cardiovascular disease (CVD).1 2 However, 
data from the Mayo clinic3 and a previous UK 
study showed no increase in CVD admissions in 
patients with RA, despite an increase in CVD mor-
tality.4 This raised the possibility that there is an 
increased case fatality among patients with RA 
admitted with CVD and/or more clinically silent 
disease. We sought to explore this issue further by 
comparing the rates of ‘ﬁ  rst’ admission for CVD in 
a cohort of patients with early inﬂ  ammatory poly-
arthritis (IP) (of which RA is a large subset) and in a 
matched sample of the general population. We also 
examined mortality from CVD over the same time 
period in this cohort.
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METHODS
Patients
Patients recruited by the Norfolk Arthritis Register 
(NOAR), a primary care-based inception cohort 
based in Norwich, UK, with a symptom onset 
between 1995 and 1999 formed the study popula-
tion. Recruitment methods for the NOAR cohort 
have been described in detail elsewhere.5 In brief, 
patients were referred to NOAR if they were aged 
at least 16 years and had consulted a physician 
within the study area for recent-onset synovitis 
affecting ≥2 joints lasting ≥4 weeks. Patients with 
a diagnosis other than RA, undifferentiated IP, pso-
riatic arthritis (PsA) or post-infective arthritis are 
excluded from NOAR, although the speciﬁ  c diag-
noses of remaining patients are not recorded as 
they are within the classiﬁ  cation of IP. Structured 
interviews and physical examinations were con-
ducted by trained research nurses at baseline for all 
subjects. Baseline serum samples were later tested 
for rheumatoid factor (RF), anti-cyclic citrullinated 
peptide antibody (ACPA) and C-reactive protein 
(CRP). Baseline Health Assessment Questionnaires 
(HAQs)6 were completed by all subjects. Patients 
were classiﬁ   ed as ‘physically inactive’ if they 
reported any difﬁ  culty (some difﬁ  culty, much dif-
ﬁ  culty or unable to do) in response to the question: 
‘Are you able to walk outdoors on ﬂ  at ground?’. 
Patients were classiﬁ   ed as past smokers, current 
or never smokers based on self-reported history of 
cigarette smoking. Finally, patients were classiﬁ  ed 
as being exposed or not to any disease-modifying 
antirheumatic drugs (DMARDs, excluding steroids), 
methotrexate (MTX), steroids or non-  steroidal 
  anti-inﬂ  ammatory drugs (NSAIDs, excluding low-
dose aspirin) at baseline.
Follow-up
Patients were followed annually for 2 years after 
symptom onset. Subjects diagnosed at any time 
during follow-up with a condition (excluding RA, 
PsA or post-infective arthritis) that explained their 
symptoms were excluded from the analysis. The 
1987 American College of Rheumatology (ACR) 
criteria for RA7 were applied cumulatively up to 
2 years from symptom onset and subjects were 
categorised as having RA if they ever satisﬁ  ed the 
criteria. The remaining subjects were categorised 
as having undifferentiated IP. All subjects were 
‘ﬂ   agged’ with the Ofﬁ   ce for National Statistics 
(ONS) who provided notiﬁ  cation if the patient died 
together with a copy of the death certiﬁ  cate.
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The NOAR cohort data were linked to the electronic admis-
sions system of the region’s only acute hospital. This elec-
tronic admissions record system was established in January 
1995. Record linkage enabled the identiﬁ   cation of patients 
admitted to hospital between January 1995 and March 2004 
including the date and reason for admission (coded using 
the International Classiﬁ   cation of Diseases, 10th Revision 
(ICD10)).8 Patients admitted to hospital for any of the follow-
ing conditions were included in the analysis: ‘vascular disease’ 
(any condition from Chapter I of ICD10); ‘CVD’ I00–I52.8; 
‘coronary heart disease’ (CHD) I20–I25; or ‘stroke’ I60–I64. 
Length of follow-up was calculated from the date of onset of 
IP symptoms until the earliest of the date of ﬁ  rst admission 
for a vascular event, death, emigration or 31 March 2004 (the 
end of the study period). For each grouping detailed above, 
hospitalisation rates per 1000 person years were calculated for 
the study population and stratiﬁ  ed by gender. Mortality was 
studied for the same time period. Cause of death was taken 
from the death certiﬁ  cate.
Admissions data for the general Norfolk population were 
obtained from the regional public health observatory. These 
data were used to compute comparative age-, sex- and calendar 
year-speciﬁ  c hospitalisation rates for each category of vascular 
disease excluding heart failure (data on this outcome in the gen-
eral population were unavailable). For both the NOAR cohort 
and the Norfolk population, only the ﬁ  rst admission for vascular 
disease was considered throughout the follow-up period. Thus, 
each patient could only contribute one event in the current 
analysis.
ONS also provided death rates for the general Norfolk 
  population from 1 January 1995 to 31 March 2004 for all-cause, 
‘vascular disease’, CVD and CHD mortality.
Statistical analysis
Hospitalisation rates for the NOAR cohort were compared with 
those of the Norfolk population. These comparison rates were 
used as offset values in a Poisson regression to compute age, sex 
and calendar year relative risk (RR) (with their corresponding 
95% CI) for groupings of vascular disease.
To compare the mortality risks of the NOAR cohort with 
those of the Norfolk population, standardised mortality ratios 
(SMRs) were estimated for all-cause, ‘vascular disease’ and CVD 
mortality by gender and within seropositive subgroups.
The association between lifestyle/demography, disease 
severity/activity and treatment factors and hospital admis-
sion for vascular disease was explored univariately within the 
cohort using Poisson regression. The lifestyle/demographic 
  factors considered were: age at IP onset; gender (male vs 
female); smoking history at baseline (current vs never, past vs 
never); any difﬁ  culty walking at baseline (vs no difﬁ  culty). The 
following factors were considered as markers of disease sever-
ity/activity: cumulative RA status (ACR criteria, see above; yes 
vs no); baseline RF status (positive vs negative); baseline ACPA 
status (positive vs negative); baseline CRP concentration (mg/l); 
and baseline HAQ score. Finally, the following treatments were 
considered: baseline exposure to DMARDs, MTX, steroids or 
NSAIDs (yes vs no).
RESULTS
Between 1995 and the end of 1999, 800 patients were referred to 
the NOAR with a symptom onset after 1 January 1995 who did 
not receive a consultant diagnosis other than RA, PsA, postviral 
arthritis or undifferentiated IP during follow-up. Table 1 shows 
the characteristics of these patients. Linkage with the admis-
sions database of the region’s main hospital was possible for all 
800 patients.
The patients were followed via the record linkage for a 
total of 5486 person-years from symptom onset, giving a 
median follow-up of 7.0 years (IQR 5.8–8.1). During this 
period 112 patients were hospitalised for a vascular condition. 
Hospitalisation rates for each grouping of vascular disease are 
shown in table 2. RR for ﬁ  rst admission for each grouping of 
vascular disease compared with the expected regional hospi-
talisation rates are also shown in table 2. The risk of hospitali-
sation for all vascular diseases combined, CVD and CHD was 
approximately doubled in patients with IP compared with the 
general population. There was no association between IP and 
hospitalisation for stroke.
During the same period 94 patients died, 53 of whom (56.4% 
of all deaths) had a vascular condition recorded as the under-
lying cause of death. Table 3 shows the SMRs for all-cause, 
vascular disease and CVD mortality. All-cause mortality was 
slightly higher in the NOAR cohort than the local population 
but this was not statistically signiﬁ  cantly. Mortality for vas-
cular disease and CVD were also higher in the NOAR cohort 
but not signiﬁ  cantly so. All-cause mortality was not increased 
in either the RF positive subgroup or the ACPA positive 
  subgroup. CVD mortality was increased 53% in women who 
were positive for RF and was doubled in women who were 
positive for ACPA. However, these values were not statisti-
cally signiﬁ  cant.
Table 4 shows the risk of admission for CVD associated with 
demographic, lifestyle and disease-related factors within the 
NOAR cohort. Increasing age and male gender were associated 
with an increased (unadjusted) risk of CVD admission. Patients 
reporting any difﬁ  culty walking as part of the HAQ at baseline 
were nearly twice as likely to be hospitalised for CVD as those 
without any such difﬁ  culty. Interestingly, there was no signiﬁ  -
cant association between baseline smoking status or CRP and 
risk of CVD, although this may be due to a lack of statistical 
power.
Table 1  Cohort characteristics at baseline
Characteristic
n/N (%), mean (SD) or 
median (IQR)*
Mean (SD) age at IP onset (years) 55.4 (16.6)
Median (IQR) symptom duration (months) 6.4 (3.6–12.0)
Gender: female, n/N (%) 536/800 (67.0)
Smoking history
  Past smoker, n/N (%) 301/797 (37.8)
  Current smoker, n/N (%) 164/797 (24.3)
  Never smoker, n/N (%) 465/797 (58.3)
Walking 5 m: any difﬁ  culty, n/N (%) 178/637 (27.9)
Positive for rheumatoid factor, n/N (%) 213/717 (29.7)
Positive for ACPA, n/N (%) 228/708 (32.2)
Mean (SD) CRP concentration (mg/l) 16.1 (27.0)
Mean (SD) HAQ score 0.84 (0.74)
DMARD use, n (%) 253/800 (31.6)
MTX use, n (%) 136/800 (17.0)
Steroid use, n/N (%) 134/800 (16.8)
NSAID use, n/N (%) 505/800 (63.1)
Statin use, n/N (%) 8/800 (1.0)
Cumulative ACR criteria for RA after 2 years: 
met criteria, n/N (%)
387/800 (48.4)
*Denominator denotes number of patients for whom data were available.
ACPA, anticyclic citrullinated peptide antibody; ACR, American College of 
Rheumatology; CRP, C-reactive protein; DMARD, disease-modifying antirheumatic 
drug; HAQ, Health Assessment Questionnaire; IP, inﬂ  ammatory polyarthritis; MTX, 
methotrexate; NSAID, non-steroidal anti-inﬂ  ammatory drug; RA, rheumatoid arthritis.
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However, the study population was no more likely to be hos-
pitalised for vascular disease than the general population. This 
contrast in results could be due to differences in the patients 
studied (early RA vs early IP). It is possible that patients in our 
‘milder’ IP cohort are more likely to have ‘milder’ CVD events—
that is, resulting in hospitalisation rather than death—than the 
early RA cohort. Also, the Stockport study considered all hospi-
tal admissions per patient whereas our analysis compared the 
rate of ﬁ  rst (post-IP onset) hospitalisation only. On the basis of 
their results, Goodson et al4 hypothesised that patients with RA 
have an increased post-CVD event case fatality compared with 
the general population.
Certain results from this study were somewhat unexpected. 
First, it is widely recognised that the risk of CVD in the general 
population is increased in subjects with a history of smoking10 11 
as well as a raised high sensitivity CRP concentration.11–13 Our 
study failed to detect a signiﬁ  cantly increased risk of CVD with 
either of these factors. A lack of association between smoking 
and cardiovascular mortality has previously been reported in 
NOAR1 and other RA cohorts.14
Finally, the risk of admission for CVD within the NOAR 
cohort was explored by patient baseline treatment status 
(table 5). Exposure to any DMARD, MTX or steroids was 
not associated with a signiﬁ  cantly increased (adjusted) risk. 
However, patients who were taking NSAIDs at baseline were 
half as likely to be admitted for CVD as patients who were 
not using these agents.
DISCUSSION
Results from the present study show that, in Norfolk, patients 
with a recent onset of IP were twice as likely to be hospitalised 
for a vascular condition as the general population (adjusted for 
age and gender). A similar doubling of risk was observed for 
CVD and CHD (as deﬁ  ned in this study), although no increase in 
hospital admission for stroke was observed. Difﬁ  culty in walk-
ing was the only factor associated with a signiﬁ  cant increase in 
CVD admission risk in patients with IP. We also found a modest 
increase in CVD mortality which was more marked in women. 
This increase in mortality was less marked than that observed 
in patients recruited by NOAR with a symptom onset between 
1990 and 1994 after a similar length of follow-up.1 9 As in our 
previous studies, the increased risk of CVD mortality was mainly 
seen in RF-positive and ACPA-positive women, although the 
results did not reach statistical signiﬁ  cance in the present study.
Interestingly, the ﬁ   ndings of this study are in contrast to 
those of a similar study based in Stockport, UK.4 In that study, 
Goodson et al studied the risk of death from and hospital admis-
sion for ‘all vascular disease’ in a population of patients with 
RA, as identiﬁ   ed through rheumatology clinics. Patients in 
their cohort were 1.4 times (men) and 1.9 times (women) more 
likely to die from vascular disease than the general population. 
Table 4  Demographic/lifestyle and disease-related predictors of CVD 
admission 
Factor
Number with CVD 
admission 
(% of group)
Unadjusted 
RR 95% CI
Adjusted* 
RR 95% CI
Age at symptom 
onset (per decade)
64 1.8 1.5 to 2.2 – –
Gender
 Female 30  (5.6) 1 Referent – –
  Male 34 (12.9) 2.4 1.5 to 4.0 – –
Smoker
 Never 20  (4.3) 1 Referent 1 Referent
  Past 25 (8.3) 1.3 0.7 to 2.3 0.8 0.4 to 1.4
  Current 19 (11.6) 1.6 0.8 to 2.9 1.5 0.8 to 2.8
RA by 2 years
 No 26  (6.3) 1 Referent 1 Referent
  Yes 38 (9.8) 1.6 0.96 to 2.6 1.2 0.7 to 1.9
Baseline RF
 −ve 40  (7.9) 1 Referent 1 Referent
  +ve 18 (8.5) 0.92 0.5 to 1.6 0.8 0.5 to 1.5
Baseline ACPA
 −ve 36  (7.5) 1 Referent 1 Referent
  +ve 21 (9.2) 1.2 0.7 to 2.1 1.1 0.7 to 2.0
CRP concentration 
(mg/l)
57 1.0 0.99 to 1.0 0.99 0.99 to 
1.0
Baseline HAQ 64 1.1 0.8 to 1.5 1.1 0.8 to 1.6
Walk 
  No difﬁ  culty 31 (6.8) 1 Referent 1 Referent
 Any  difﬁ   culty 26 (14.6) 2.3 1.4 to 4.0 2.0 1.2 to 3.5
*Adjusted for age, gender and calendar year.
ACPA, anticyclic citrullinated peptide antibody; CRP, C-reactive protein; CVD, 
cardiovascular disease; HAQ, Health Assessment Questionnaires; RA, rheumatoid 
arthritis; RF, rheumatoid factor; RR, relative risk.
Table 2  Admission rates for vascular disease and relative risk (RR) for ﬁ  rst admission
Site (ICD10 codes) N
First admission rate per 1000 person-years (95% CI)
Observed Expected RR (95% CI) Women Men Total
CVD (I00–I53) 64 8.1 (5.5 to 11.5) 19.2 (13.3 to 26.8) 11.7 (9.0 to 14.9) 64 32.9 1.9 (1.5 to 2.5)
CHD (I20–I26) 32 3.0 (1.5 to 5.3) 11.8 (7.3 to 18.1) 5.8 (4.0 to 8.2) 32 17.1 1.9 (1.6 to 2.3)
Stroke (I60–I64) 9 1.6 (0.8 to 3.1) 1.7 (0.3 to 4.9) 1.6 (0.6 to 3.5) 9 8.4 1.1 (0.6 to 2.0)
All vascular disease 
(I00–I98X)
112 15.4 (11.6 to 19.9) 31.0 (23.3 to 40.3) 20.4 (16.8 to 24.6) 112 54.8 2.0 (1.7 to 2.5)
CHD, coronary heart disease; CVD, cardiovascular disease; ICD10, International Classiﬁ  cation of Diseases, 10th Revision.
Table 3  SMRs for all-cause, vascular disease and CVD mortality by 
gender, overall and for seropositive subgroups
 
Main cause of death
All-cause Vascular disease CVD
SMR (95% CI) SMR (95% CI) SMR (95% CI)
Whole cohort
  Men 1.02 (0.73 to 1.38) 1.06 (0.63 to 1.68) 0.95 (0.47 to 1.70)
  Women 1.16 (0.87 to 1.52) 1.21 (0.76 to 1.83) 1.52 (0.87 to 2.48)
  Total 1.10 (0.88 to 1.34) 1.14 (0.81 to 1.56) 1.22 (0.81 to 1.78)
RF-positive subgroup
  Men 1.12 (0.61 to 1.87) 0.93 (0.30 to 2.16) 1.07 (0.29 to 2.74)
  Women 1.20 (0.66 to 2.02) 1.11 (0.36 to 2.59) 1.53 (0.42 to 3.91)
  Total 1.16 (0.69 to 1.23) 1.01 (0.48 to 1.86) 1.26 (0.54 to 2.48)
ACPA-positive subgroup
  Men 1.18 (0.65 to 1.98) 0.79 (0.21 to 2.02) 0.85 (0.18 to 2.49)
  Women 1.25 (0.68 to 2.10) 1.42 (0.52 to 3.08) 2.01 (0.65 to 4.68)
 Total 1.22 (0.81 to 1.76) 1.07 (0.51 to 1.97) 1.33 (0.57 to 2.62)
ACPA, anticyclic citrullinated peptide antibody; CVD, cardiovascular disease; RF, 
rheumatoid factor; SMR, standardised mortality ratio.
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The degree of increase in CVD SMR in RF- and ACPA-positive 
patients has fallen based on the ﬁ   ndings in NOAR patients 
recruited between 1990 and 1994.1 9 In the 1990–4 cohort the 
SMR in RF-positive women in NOAR was 2.02 compared with 
1.53 in the present study. There are a number of possible expla-
nations for this. The natural history of RF-positive IP may be 
changing and the disease may be becoming milder. In addition, 
disease-modifying therapy is becoming more aggressive and 
is started earlier. Thus, any excess in CVD mortality may not 
be seen until later in the disease course. This is likely if the 
cumulative burden of inﬂ  ammation is a signiﬁ  cant predictor of 
excess cardiovascular mortality in patients with RF-positive IP. 
It is also possible that the management of CVD has improved 
and so patients are surviving longer after their ﬁ  rst manifesta-
tion of CVD. Another reason for the differences in the ﬁ  ndings 
between this and earlier studies may be the switch from ICD 
versions 9–10 (used from 1994) to classify the cause of death. 
The diseases included in the ‘circulatory disease’ chapter in ver-
sion 9 do not directly map to the equivalent chapter in version 
10. Further follow-up of this cohort is needed to see if the SMR 
due to CVD in RF-positive patients changes with time.
This study detected a reduced risk of CVD in patients in 
NOAR who were exposed to NSAIDs at baseline compared with 
those who were not. This ﬁ  nding is unexpected given the recent 
publicity with regard to a potential link between NSAID expo-
sure and CVD mortality.15 However, we have recently reported 
that NSAID use assessed cumulatively in patients from NOAR is 
not associated with increased cardiovascular mortality.16 In our 
cohort, this ﬁ  nding may represent a ‘healthy user’ effect in terms 
of which patients are prescribed NSAIDs.
This is the ﬁ  rst study to explore the risk of admission for 
vascular disease in a primary care-based population of patients 
with recent-onset IP. The study is unaffected by the potential 
recruitment bias often associated with studies focusing on 
patients with RA recruited solely through hospitals or clinics. 
A particular strength of this study was the focus on patients 
with IP of very recent onset and the possibility of record link-
age from the date of symptom onset, thus minimising left 
censorship.
However, there are some methodological issues that require 
consideration. Record linkage could only be achieved from 
1995 onwards. This coincided with a 5-year recruitment period 
in NOAR (1995–9) in which most subjects were only followed 
for 2 years from symptom onset. We are therefore unable 
to analyse, for example, cumulative disease activity or drug 
exposure as a predictor of subsequent admission. The study 
cohort includes patients with undifferentiated IP as well as 
patients who could be classiﬁ  ed as having RA according to the 
ACR criteria.7 The increased risk observed in this study may 
therefore underestimate the level of risk in patients with RA. 
The ACR criteria are known to be relatively unstable in early 
arthritis,17-19 and thus we feel the focus on IP is justiﬁ  able. In 
this study population, slightly less than half of the patients met 
the ACR criteria applied cumulatively by 2 years from symp-
tom onset. Importantly, the risk of hospital admission for CVD 
in the RA subgroup was no different from that of the com-
plete cohort (RR=1.8, 95% CI 1.2 to 2.7) and the results for the 
predictive analyses were essentially identical. Also, we have 
previously shown that RA status is a poor predictor of CVD 
mortality.1 We did not have access to individual patient level 
data for the background Norfolk population which may have 
been insightful, such as traditional CVD risk factors or drug 
treatment history.
Difﬁ  culty in walking may be viewed as a lifestyle factor for 
the risk of CVD as these patients are less mobile than those 
with no difﬁ  culty and people who take more exercise are prob-
ably at a lower risk of a CVD event. It may also be viewed as 
a disease-related factor because patients with the most severe 
  disease will have the greatest physical disability preventing 
them from walking. An approach that encompasses both good 
disease management and improvement in lifestyle may reduce 
the risk of CVD.
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